Abstract
Get full access to this article
View all access options for this article.
References
1.
Bellmunt
J
de Wit
R
Vaughn
DJ
et al.
Pembrolizumab as second-line therapy for advanced urothelial carcinoma . N Engl J Med 2017 ; 376 : 1015 –1026 .
2.
Ferris
RL
Blumenschein Jr
G
Fayette
J
et al.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck . N Engl J Med 2016 ; 375 : 1856 –1867 .
3.
Motzer
RJ
Escudier
B
McDermott
DF
et al.
Nivolumab versus everolimus in advanced renal-cell carcinoma . N Engl J Med 2015 ; 373 : 1803 –1813 .
4.
Borghaei
H
Paz-Ares
L
Horn
L
et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer . N Engl J Med 2015 ; 373 : 1627 –1639 .
5.
Robert
C
Schachter
J
Long
GV
et al.
Pembrolizumab versus ipilimumab in advanced melanoma . N Engl J Med 2015 ; 372 : 2521 –2532 .